OH-PROCTER-&-GAMBLE
5.8.2021 20:51:08 CEST | Business Wire | Press release
As an Olympic sponsor for the past 10 years, Procter & Gamble’s (NYSE: PG) focus is on celebrating and supporting the unique journeys athletes take on the road to their Olympic dreams, including the causes they champion and the work they do to drive positive change in their communities. In the lead up to the Olympic Games Tokyo 2020, P&G was inspired by the selfless actions of Olympic and Paralympic athletes around the world who stepped up and served others. This led P&G to create the Athletes for Good Fund in partnership with the International Olympic Committee (IOC) and International Paralympic Committee (IPC). Its purpose is to honor and fuel the work of Olympic and Paralympic athletes and hopefuls who lend their time, talent, and resources to charitable causes in the areas of Community Impact, Equality & Inclusion, and Environmental Sustainability. For Tokyo 2020, Athletes for Good Fund provided more than $500,000 in grants to help fuel the efforts of the recipients’ charities of choice.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210805005996/en/
Today, during a virtual panel discussion dubbed “Champions and the Causes They Champion,” co-hosts Olympic Gold Medalist Nastia Liukin (USA, Gymnastics Legend) and Olympic Silver Medalist Gus Kenworthy (Great Britain, Freestyle Skiing) were joined by four athletes who are not only incredible competitors, but also display compassion, humanity, and goodness on and off the field of play. Through their inspiring stories, we learned how each panelist found motivation based on their personal experiences, along with their passion to get involved to create positive change within their communities. Panelists included:
- Mariah Duran* , USA, Skateboarding: Having experienced firsthand the intimidation of competing in a male-dominated sport with few female mentors, Mariah serves as a role model, mentor, and advocate for young girls in skate. Through her work with Skate Like A Girl, she encourages the next generation of girls to continue pursuing their passion.
- Alice Dearing* , Great Britain, Swimming: As the first Black woman to swim for Team Great Britain at any Olympic Games, Alice has experienced the barriers within the sport of swimming that are faced among people of color. Taking matters into her own hands, Alice is a lead ambassador for the Black Swimming Association (BSA), focusing on increasing participation and changing attitudes to attract more Black people to understand the importance of learning to swim.
- Brian Afanador* , Puerto Rico, Table Tennis: After Hurricane Maria left a devastating effect on Puerto Rico, Brian used his platform as an Olympic athlete to expand awareness to help his community. In collaboration with #Yonomequito Foundation, he has helped to rebuild homes and provide necessities, like food, fresh water, and emergency services to local families in need.
- Erica Sullivan , USA, Swimming: As an openly gay, Asian American swimmer, Erica has stepped up to advocate for intersectional equality in sport. During Tokyo 2020, she used her press conference as an opportunity to bring awareness to minority groups, including the LGBTQ+ community.
“The spirit of the Olympic Games has the power to lift us up and unite us, and these incredible athletes have all taken that spirit beyond the Olympic and Paralympic Movement, and into their communities with a goal of creating positive change,” said host Nastia Liukin. “It’s inspiring to see organizations, like P&G, continuing to celebrate athletes both on and off the field, supporting their efforts to fuel good in communities so others will be inspired to do the same.”
“For me, being an Olympian is much more than just excelling at my sport; it’s also about using my platform to help the next generation of women skaters coming up reach their potential and dream big,” Mariah Duran shared. “I would not be where I am today without the community and experiences I got at Skate Like A Girl. This organization is a prominent voice for gender equality and inclusion in skateboarding and their events, camps and after school programs help make an unreal scenario, real. I am so appreciative of P&G and Athletes for Good for supporting them.”
You can view the full panel conversation here .
*Athletes for Good Fund Grant recipient
Spotlighting Those Who Lead with Love During Tokyo 2020
Throughout Tokyo 2020, P&G took its commitment to supporting athletes a step further by donating an additional two grants to the chosen charities of athletes who used their Olympic Games platform to serve and support others in Tokyo. Along with Erica Sullivan, P&G extended a donation to Pita Taufatofua (Tonga, Taekwondo), who inspired people everywhere with his generosity towards the athlete community on the ground in Tokyo. The three-time Olympian, who has 15 years of volunteer experience in the youth mental health space, publicly recognized the immense amount of pressure that athletes are put under when competing at an elite level and invited athletes to reach out to him for counseling and advice. His call to action resulted in hundreds of exchanges with athletes, both via social media and in-person at Tokyo 2020. For his efforts to serve as a sounding board for athletes and provide an uplifting voice of support, P&G is proud to recognize that the good that Pita does, is what truly makes him great.
The Athletes for Good Fund and Tokyo 2020 athlete grant donations are helping P&G to achieve its goal of reaching 2,021 Acts of Good in 2021 to support its Lead with Love campaign.
You can learn more about P&G’s Lead with Love commitment here: https://us.pg.com/lead-with-love/ .
About P&G’s 2,021 Acts of Good in 2021
At P&G, supporting our communities, fostering equality and inclusion, and protecting the planet is embedded in how we do business. We believe we have a responsibility to help improve everyday life — through the products we create and the positive impact our brands and Company can have. Under our Lead with Love campaign, P&G and its brands have committed to 2,021 acts of good this year.
About Procter & Gamble
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit https://www.pg.com/ for the latest news and information about P&G and its brands.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210805005996/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
